Recent controversy in the United States regarding the overprescribing of testosterone replacement therapy to aging men, and cardiovascular side effects associated with the hormones, have prompted the European Menopause and Andropause Society (EMAS) to issue a statement saying testosterone treatments should not be offered to all aging men, and that candidates be evaluated for co-morbidities that could affect natural testosterone levels and increase side effects from treatment. Testosterone treatments, which includes the brand names AndroGel and Axiron, are intended for men who suffer from hypogonadism, a condition in which men do not produce enough testosterone due to disease or injury. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.